Chromosome changes in patients treated with "Myleran"

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Chronic myeloid leukemia is a significant hematologic malignancy.
• Myleran (busulfan) is a cytostatic agent used in leukemia treatment.
• Understanding drug-induced chromosomal changes is crucial for patient safety.

Purpose of the Study:

• To determine if Myleran causes chromosomal changes in chronic leucosis patients.
• To assess the safety profile of Myleran regarding genotoxicity.
• To correlate Myleran therapy with observed cytogenetic alterations.

Main Methods:

• Patients with chronic leucosis received daily oral doses of Myleran (4 mg).
• Peripheral blood leucocytes were analyzed for chromosomal aberrations using established cytogenetic methods.
• Dose-response and total dose effects were considered.

Main Results:

• No additional visible chromosomal aberrations were detected in leucocytes beyond those typically associated with chronic leucosis.
• Analysis was performed on patients receiving relatively small total doses of Myleran.
• The cytostatic did not appear to induce new aberrations at the studied doses.

Conclusions:

• Myleran, at the therapeutic doses and total amounts studied, did not induce significant chromosomal aberrations in chronic leucosis patients.
• The observed chromosomal changes were consistent with the underlying disease, not Myleran treatment.
• Further studies with higher cumulative doses may be warranted.